Key Takeaways
- Axon fell 11.3% intraday on September 15, sliding to $434.98, within about 2% of the $424.69 close that marked its low point for all of 2026.
- The premarket reaction to Axon’s new $1 billion convertible note was estimated at only about 3.5%, so the note alone does not explain the fuller drop.
- The stock’s forward price to earnings multiple has fallen from a mean of 81.07 times to 54.55 times today, sitting much closer to its cycle low of 44.43 times than to that mean.
- Cash fell 58% from a $1.42 billion peak in September 2025 to $600 million by June 2026, a more concrete explanation for the timing of this raise than dilution fear alone.
A Convertible Note Did Not Cause an 11% Drop
Axon Enterprise (AXON) stock dropped 11.3% intraday on September 15, falling from a prior close near $490 to $434.98 by mid morning. The trigger cited in the day’s news flow was a new $1 billion offering of zero percent convertible senior notes due 2031, with underwriters holding an option for another $150 million.
That framing does not hold up against the size of the move. Reuters priced the note’s initial premarket impact at roughly 3.5%, based on shares trading near $473 before the open. A convertible offering that carries no coupon and includes capped calls to blunt dilution is a routine financing tool, not the kind of news that typically erases an eighth of a company’s market value in a single session.
The fuller explanation sits in Axon’s valuation history. Its forward price to normalized earnings multiple has averaged 81.07 times over 3 years peaked at 131.18 times, and now sits at 54.55 times, just 10 points above the 44.43 times low. That is a multiple that has already spent most of 2026 compressing, not one cracking for the first time today.
Today’s close also lands within about 2% of the $424.69 low Axon set on March 31, 2026. The stock has now round-tripped from that trough to a partial recovery near $560 in June and back down again, which frames the convertible note as the catalyst for a retest of an already established floor rather than a new shock.
Wall Street’s Targets to AXON Have Been Lagging All Year
Street mean price targets for Axon have stayed above the trading price every quarter for more than a year, but the size of that gap has moved in a way that undercuts using it as a reliable floor. As of September 14, the mean target stood at $706.21 against a $490.18 close, a target to price ratio of 144%.
That gap is not new. It ran from 87% in June 2025 to as high as 173% in March 2026, before narrowing to 118% in June 2026 and widening again to 144% by mid September. The pattern is a moving target, not a fixed anchor investors can lean on.
The more telling number is the pace of change on each side. Axon’s mean target fell about 21%, from $888.93 in September 2025 to $706.21 a year later. Over the same period, the stock itself fell about 32%, from $717.64 to $490.18. Analysts have been cutting numbers, just more slowly than the market has been repricing the stock.
Coverage has also stayed heavily bullish through the entire decline. Of the 23 ratings recorded as of September 14, 10 are buys and 8 are outperforms, against just 3 holds and a single underperform. That skew held through a period when the stock lost roughly 47% of its value from its $827.94 close on June 30, 2025, which is reason to treat the current consensus target as a lagging indicator rather than a support level.
AXON Stock’s Balance Sheet Explains the Timing
The more concrete case for why Axon raised $1 billion now sits on the balance sheet rather than in the stock chart.
Cash and equivalents peaked at $1.42 billion on September 30, 2025, fell for two straight quarters to $460 million by March 31, 2026, and only partly recovered to $600 million by June 30, 2026, still a 58% decline from the peak.
Total debt did not rise to match that cash drawdown. It actually eased slightly over the same stretch, from $2.10 billion to $1.85 billion, so the shrinking cash position was not offset by new borrowing before this note.
That drawdown lines up with what management described on the Q2 call: heavy inventory investment to support demand and reduce supply chain risk, alongside a free cash flow outflow of just $1 million for the quarter, an improvement from a $92 million outflow a year earlier but still far short of the $450 million full year figure management has guided to. Management has said that figure depends on a seasonally strong fourth quarter.
Structured as a zero coupon note with capped calls to limit share dilution, no issuer redemption before September 2029, and a holder put option in 2031, this raise reads as a pre-funded cushion against a cash position that had already thinned considerably, not as new leverage layered onto a business under stress.
Conclusion
The evidence points to a stock that has been re-rating for more than a year on rate sensitivity and margin scrutiny, with today’s convertible note serving as the occasion for a retest of a floor near $425 to $435 rather than the cause of a new decline. The multiple has already compressed most of the way to its cycle low, and the balance sheet data explains why management chose to raise cash now rather than a genuine liquidity emergency.
The open risk is whether the fourth quarter free cash flow that management’s full year guidance depends on actually materializes. Operating cash flow was barely positive in the second quarter despite 35% revenue growth, and the inventory build that has drained cash over the past three quarters has to unwind for that guidance to hold.
The next disclosure that would move this thesis is the third quarter report, specifically whether free cash flow starts converging toward the pace needed to hit $450 million for the year, and whether adjusted gross margin recovers in the fourth quarter as management has guided, given that memory costs were flagged as a headwind through the third quarter with no relief expected until new supply arrives in 2028. A quarter where cash generation still lags revenue growth would suggest the balance sheet strain behind this note has not fully resolved, regardless of where the stock trades.
Should You Invest in Axon Enterprise, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AXON stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AXON alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze AXON stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
